ConductScience.org, home

Gene · 4055

LTBR: lymphotoxin beta receptor

12 sourcesgene-search-2026-11-11-0.2.0

Download JSON
Cite this record

ConductScience Library. LTBR: lymphotoxin beta receptor. Genes, record 4055. Release gene-search-2026-11-11-0.2.0, 11 Nov 2026. https://conductscience.org/library/genes/4055

On this page

Gene

Symbol
LTBR
HGNC
Name
lymphotoxin beta receptor
HGNC
NCBI Gene ID
4055
NCBI Gene
HGNC ID
HGNC:6718
HGNC
Ensembl
ENSG00000111321
NCBI Gene
Aliases
D12S370, LT-BETA-R, TNF-R-III, TNFCR, TNFR-RP, TNFR2-RP, TNFR3, TNFRSF3
NCBI Gene
Type
protein-coding
NCBI Gene

Proteins1

Reviewed human proteins whose Swiss-Prot entry states the gene.

UniProt entryProteinLengthStructuresGene stated in
P36941Tumor necrosis factor receptor superfamily member 34352Ensembl, GeneID, HGNC

Source UniProt

Patents104

Patents whose sequence listing contains this protein's exact sequence. A patent can list a sequence without claiming it.

PublicationPublishedSEQ ID NOProteinSource
EP 4724490 A22026-04-151P36941Espacenet
WO 2026019692 A22026-01-2229P36941Espacenet
EP 4650780 A22025-11-19716P36941Espacenet
EP 4642792 A12025-11-0554P36941Espacenet
JP 2025147176 A2025-10-068143P36941Espacenet
JP 2025147176 A2025-10-0616767P36941Espacenet
JP 2025131712 A2025-09-095P36941Espacenet
JP 2025529142 A2025-09-042489P36941Espacenet
JP 2025529142 A2025-09-046944P36941Espacenet
WO 2025184170 A12025-09-0438P36941Espacenet

1 to 10 of 104

See all 104 patents

Drugs1

Drugs a ChEMBL mechanism record says act on the gene's protein, through Open Targets.

DrugChEMBL IDMechanismAction
HCBE-11CHEMBL2109509Tumor necrosis factor receptor superfamily member 3 agonistAGONIST

Source ChEMBL

Trials0

Trials of those drugs. A trial joins the gene only through a drug that acts on it.

None in this release.

NIH grants2,138

NIH grants whose papers are about the gene, through NIH's grant-paper links.

GrantTitleLTBR papersNewest fiscal year
P30CA016672Cancer Center Support Grant162025
U19AI070535Airway Inflammation and Airway Remodeling in Severe Asthma132025
P30CA044579University of Virginia Cancer Center Support Grant102025
P30CA008748Cancer Center Support Grant92025
T32AI007496Interdisciplinary Training Program in Immunology72025
P01CA065493Off-the-Shelf Immune Effector Cells for Hematological Malignancies52025
P30CA047904Cancer Center Support Grant52025
T32CA154274Training Grant in Cancer Biology52025
P30AR070253Joint Biology Consortium Resource-based Center42025
P30CA068485Cancer Center Support Grant42025

1 to 10 of 2,138Source NIH's project files

See all 2,138 nih grants

Papers3,299

Newest first. Swiss-Prot's references are curated; PubTator's text mining finds papers that name the gene, not always ones about it.

TitleJournalYearPMIDFound bySource
Tertiary lymphoid structures in urothelial carcinoma: bridging spatial architecture with therapeutic vulnerability in the post-BCG era.Front Immunol202642774854PubTator, text miningPubMed
Youthful systemic factors restore aged liver regeneration through LTβ-driven hepatocyte reprogramming.J Hepatol202642772698PubTator, text miningPubMed
Immunogenic cell death and tertiary lymphoid structures: bridging tumour cell death and immune organization.Nat Rev Immunol202642749753PubTator, text miningPubMed
Daily HIV pre-exposure prophylaxis enhances monocyte activation and reprogrammes immune cell metabolism.Front Immunol202642666216PubTator, text miningPubMed
TNFSF14/LIGHT responses in intestinal and oesophageal fibroblasts are differentially modulated by hydroxylase inhibitors.J Physiol202642516061PubTator, text miningPubMed
Radiotherapy and tertiary lymphoid structures: balancing immune activation and immune damage in cancer immunotherapy.Mol Cancer202642482188PubTator, text miningPubMed
Targeting lymphotoxin β receptor: from mechanism to precision therapy.J Enzyme Inhib Med Chem202642377217PubTator, text miningPubMed
Radiation-Induced Tumor-Intrinsic LTβR N-Glycosylation Suppresses Pyroptosis Through TRIM28-Mediated PCBP2 SUMOylation to Promote Gastric Cancer Radioresistance.Adv Sci (Weinh)202642325190PubTator, text miningPubMed
TCF1+CD4+ T cells and microglia co-orchestrate tertiary lymphoid structures to enhance prognosis and immunotherapy in non-small cell lung cancer with brain metastases.EBioMedicine202642085932PubTator, text miningPubMed
Selective elimination of circulating effector CD8 T cells via LTβR blockade separates anti-CD137 efficacy from toxicity.Sci Adv202642018612PubTator, text miningPubMed

1 to 10 of 3,299

See all 3,299 papers

Sources 12

  • ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
  • ChEMBL, through Open TargetsCC BY-SA 3.0
  • ClinicalTrials.govNo license stated
  • EMBL-EBI's patent proteinsNo added restrictions. Attribution expected
  • GenBank's patent filesNo restrictions from NCBI. Submitters may hold rights
  • HGNCCC0
  • NCBI GenePublic domain (US government)
  • NIH's project files and grant-paper linksPublic domain
  • Open TargetsCC0 1.0
  • PubMedNLM's terms
  • PubTator 3Public domain
  • UniProtCC BY 4.0
Each source's terms
  • ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
  • ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
  • ClinicalTrials.govnone stated
  • EMBL-EBI's patent proteinsEMBL-EBI's patent protein files from the EPO, JPO, KIPO and USPTO. EMBL-EBI: "EMBL-EBI itself places no additional restrictions on the use or redistribution of the data available via its Data Resources and Tools other than those provided by the original data owners" and "EMBL-EBI expects attribution (e.g. in publications, services or products) for the use of any of its Data Resources and Tools." Read on 11 Nov 2026 at https://www.ebi.ac.uk/about/terms-of-use
  • GenBank's patent filesGenBank's patent files. NCBI: "NCBI places no restrictions on the use or distribution of the GenBank data. However, some submitters may claim patent, copyright, or other intellectual property rights in all or a portion of the data they have submitted." Read on 11 Nov 2026 at https://www.ncbi.nlm.nih.gov/genbank/about/
  • HGNCCC0: https://www.genenames.org/about/license/
  • NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
  • NIH's project files and grant-paper linksPublic domain (NIH RePORTER)
  • Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
  • PubMedNLM's terms
  • PubTator 3Public domain
  • UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license

ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.

For software

Read this gene from software.

The record and each of its lists are JSON, twenty rows a page. No key.

GET https://conductscience.org/api/genes/v1/4055

GET https://conductscience.org/api/genes/v1/4055/patents?page=2